Intelligence Feed event · Macro · 2026-10-12

    GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend

    Question

    GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend

    Direct answer

    Adoption of GLP-1 receptor agonists has reached 11% of the adult US population, generating continued top-line acceleration for drug manufacturers Eli Lilly and Novo Nordisk. The expanded user base is driving measurable shifts in grocery basket composition. Packaged food, snack, and beverage giants including PepsiCo, Hershey, and Mondelez face volume growth constraints as consumers curb discretionary calorie and snack purchases, challenging historical pricing power dynamics.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend”, revision 1, evidence through 2026-10-12. https://marketontology.com/market-events/2026-10-12/glp-1-usage-reaches-11-of-us-adults-shifting-grocery-and-snack-spend-a27dee

    MACRO
    GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend
    Adoption of GLP-1 receptor agonists has reached 11% of the adult US population, generating continued top-line acceleration for drug manufacturers Eli Lilly and Novo Nordisk. The expanded user base is driving measurable shifts in grocery basket composition. Packaged food, snack, and beverage giants including PepsiCo, Hershey, and Mondelez face volume growth constraints as consumers curb discretionary calorie and snack purchases, challenging historical pricing power dynamics.
    LLYNVOPEPMDLZ
    Impact
    74
    OCT 12
    SIG
    84%
    LLYNVOPEP
    GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend
    Adoption of GLP-1 receptor agonists has reached 11% of the adult US population, generating continued top-line acceleration for drug manufacturers Eli Lilly and Novo Nordisk. The expanded user base is driving measurable shifts in grocery basket composition. Packaged food, snack, and beverage giants including PepsiCo, Hershey, and Mondelez face volume growth constraints as consumers curb discretionary calorie and snack purchases, challenging historical pricing power dynamics.
    → Structural reduction in per-capita caloric intake from 11% GLP-1 penetration compresses volume growth targets for packaged snack and beverage equities.
    Impact
    Adoption of GLP-1 receptor agonists has reached 11% of the adult US population, generating continued top-line acceleration for drug manufacturers Eli Lilly and Novo Nordisk. The expanded user base is driving measurable shifts in grocery basket composition. Packaged food, snack, and beverage giants including PepsiCo, Hershey, and Mondelez face volume growth constraints as consumers curb discretionary calorie and snack purchases, challenging historical pricing power dynamics.
    Affected
    LLYNVOPEPMDLZ
    Transmission
    Structural reduction in per-capita caloric intake from 11% GLP-1 penetration compresses volume growth targets for packaged snack and beverage equities.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYdrug volume growth expanding prescription market shareUp1-3m11% of US adults are now using GLP-1 treatments like Zepbound.
    NVOtreatment expansion driving Wegovy revenue growthUp1-3mNovo Nordisk experiences surging demand as GLP-1 user base reaches 11% of US adults.
    PEPvolume demand headwind in snack categoriesDown1-3mSnack and beverage makers face lower grocery spending from GLP-1 users.
    MDLZconfectionery demand decelerationDown1-3mPackaged food producers see lower unit volumes as GLP-1 penetration rises.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    LLYUp1188.72 2026-10-07PendingPendingPending
    PEPDowndisagreed126.68 2026-10-12+0.49%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month